Cancer Advisor

Edited and Updated: June 2026  Caution to the Reader: This is a complex, evolving topic rooted in molecular biology and evolutionary dynamics. The material below has been distilled for clinical accessibility while preserving strict mechanistic accuracy. Key conceptual frameworks from the Care Oncology Clinic (COC) protocol and Thomas Seyfried’s press–pulse model are integrated throughout. Introduction Clinicians utilizing a metabolic framework often combine 4–5 repurposed prescription agents with 4–5 nutraceuticals. While this approach frequently yields 1–2 years of sustained, stable response, acquired resistance can emerge rapidly, turning stable disease into aggressive progression. When this occurs, critical clinical questions arise: How should the regimen be modified? Should mechanistically similar agents be cycled more frequently? Should dosing be intermittent rather than continuous? What ...

Prostate cancer remains one of the most widely diagnosed malignancies globally. For decades, the therapeutic roadmap has relied on a foundational paradigm: prostate cancer cells are driven by androgens. Consequently, standard care heavily prioritizes Androgen Deprivation Therapy (ADT) and next-generation androgen receptor pathway inhibitors (ARPIs). While these interventions regularly deliver impressive initial declines in tumor volume and prostate-specific antigen (PSA) markers, they inadvertently establish a high-stakes evolutionary battleground within the tumor microenvironment. By aggressively blocking the androgen axis, conventional therapies exert an intense selective pressure on malignant cells. Instead of eradicating the disease, this environment forces the cancer to adapt, mutate, and evolve. The ultimate manifestation of this survival mechanism is Lineage Plasticity, a process where common, highly treatable prostate adenocarcinoma completely changes its cellular identity, tra...